Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)
Lynn G. Dressler(University of North Carolina at Chapel Hill), Howard L. McLeod(Unknown), Kouros Owzar(Duke University), Mark J. Ratain(University of Chicago), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Dorothy Watson(University of North Carolina at Chapel Hill), Paula N. Friedman(University of North Carolina at Chapel Hill), Katherine Donahue(University of North Carolina at Chapel Hill)
Cited by 9
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k